CannabisNewsBreaks – CannAssist International Corporation (CNSC) Featured in Latest Episode of The Bell2Bell Podcast

February 17, 2021 10:36:39

CannAssist (OTCQB: CNSC), the parent company of Xceptor Labs and developer of innovative CiBiDinol technology, was featured in an episode of The Bell2Bell Podcast, produced by InvestorBrandNetwork (“IBN”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. Bell2Bell’s latest podcast features Mark Palumbo, founder and CEO of CannAssist, as he discusses the company’s CiBiDinol technology. Palumbo noted that CannAssist’s platform, which was developed as a product of the company’s subsidiary, Xceptor Labs, is capable of improving the performance of CBD and a host of other oil-soluble active ingredients, including non-CBD cannabinoids, terpenes, essential oils and oil-soluble vitamins. He also discussed the company’s business model. “Xceptor Labs uses a B2B business model. We basically can generate a raw material and customize that raw material. We can sell it to other tech houses … and, of course, for the branded companies, we can do it in such a way that we can customize what they’re looking for and help them make the claims that they seek to make,” Palumbo said in the interview. “The other side of the business for us is B2C. We have a brand we call Xceptol. Once we were having the level of success we were with the performance of this product, we really wanted to get it to as many people as we could … to make sure that it was accessible and understandable.”

To view the full press release, visit

About CannAssist International Corporation

CannAssist, the parent company of Xceptor Labs, produces and sells its CiBiDinol technology, formulated using a proprietary process developed by the company’s founder, Mark Palumbo. Research and development aimed at enhancing the bioavailability of oil-soluble molecules resulted in the company’s CiBiDinol technology. CiBiDinol is the driving force behind CannAssist’s Xceptol brand of consumable and topical products. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, Xceptol Pain Cream is a CBD product with industry defining reliability and compliance. CannAssist believes Xceptol represents the next step for CBD products. CBD is a non-psychoactive compound found in hemp. View the company’s products on RangeMe, an online platform that enables retail buyers to efficiently discover consumer-ready, innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights and services they need. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.